Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Nanobodies to prevent hematopoietic stem cell bias and hyper-inflammation.

Project description

Overcoming cell ageing with nanobodies

Hematopoietic stem cells (HSCs) have the capacity for multiple-lineage differentiation and self-renewal, replenishing blood cells throughout the lifespan. Emerging evidence indicates that chronic inflammation damages HSCs and causes premature ageing. Intriguingly, aged HSCs exhibit heightened expression of platelet and megakaryocyte markers and a biased commitment to differentiate down the platelet pathway. As this drives excessive platelet production and causes health complications, the ERC-funded UNBIAS project aims to restore balanced HSC differentiation. To mitigate inflammation, researchers propose to use nanobodies that can erase inflammatory memories from HSCs. Unlike conventional antibodies, nanobodies consist of a single polypeptide chain and are much smaller in size, which allows them to penetrate tissues and bind tightly to specific targets.

Objective

"With a growing ageing population, there is an imminent demand to develop new therapeutic strategies to ameliorate disorders of the hematopoietic system. Our innate immune system can remember its previous encounters with inflammatory triggers. Epigenetic memories of previous inflammatory experiences throughout an individual's lifetime are imprinted in hematopoietic stem cells (HSCs), a small pool of bone marrow progenitors that give rise to all our blood cells. Inflammation harms HSCs causing their functional decline and premature ageing. It also causes long-term differentiation bias, and a heightened basal inflammatory status, known as “inlfammageing”. The most striking characteristic of aged HSCs is their increased expression of platelet and megakaryocyte markers and their commitment towards platelet biogenesis, referred to as “Platelet-bias."" Platelet bias has important consequences to human health. In our ERC starting grant project PLAT-IL-1 (714175), we discovered that platelets boost the inflammatory capacity of innate immune cells and are essential for the cytokine production of human monocytes. Our findings support that a dangerous combination of myeloid and platelet bias in inflammation-exposed HSCst results in a heightened innate immune activation. The injuries to HSCs are persistent and continue even after the clearance of the inflammatory insult, indicating that remnants of inflammatory events accrue and prolong damage to HSCs. Hence, if we could “erase"" these harmful remnants, we could UNBIAS HSCs differentiation and prevent hyper-inflammation. In our ERC-funded project, we developed novel nanobodies that efficiently eliminate remnants of inflammation in vivo. In this PoC project, we will test the ability of nanobodies to erase memories from previous inflammatory events and prevent hyper-inflammation. This project will be a stepping stone to licensing our nanobodies to industrial partners."

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

UNIVERSITATSKLINIKUM BONN
Net EU contribution
€ 150 000,00
Address
VENUSBERG-CAMPUS 1
53127 Bonn
Germany
Region
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)